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Abstract
Background: While many studies have compared the efficacy of Pap cytology, visual inspection with acetic acid (VIA) and
human papillomavirus (HPV) DNA assays for the detection cervical intraepithelial neoplasia and cancer, few have evaluated
the program effectiveness.
Methods and Findings: A population-based sample of 5603 women from Medchal Mandal in Andhra Pradesh, India were
invited to participate in a study comparing Pap cytology, VIA, and HPV DNA screening for the detection of CIN3+.
Participation in primary screening and all subsequent follow-up visits was rigorously tracked. A 20% random sample of all
women screened, in addition to all women with a positive screening test result underwent colposcopy with directed biopsy
for final diagnosis. Sensitivity, specificity, positive and negative predictive values were adjusted for verification bias. HPV
testing had a higher sensitivity (100%) and specificity (90.6%) compared to Pap cytology (sensitivity = 78.2%;
specificity=86.0%) and VIA (sensitivity=31.6%; specificity=87.5%). Since 58% of the sample refused involvement and
another 28% refused colposcopy or biopsy, we estimated that potentially 87.6% of the total underlying cases of CIN3 and
cancer may have been missed due to program failures.
Conclusions: We conclude that despite our use of available resources, infrastructure, and guidelines for cervical cancer
screening implementation in resource limited areas, community participation and non-compliance remain the major
obstacles to successful reduction in cervical cancer mortality in this Indian population. HPV DNA testing was both more
sensitive and specific than Pap cytology and VIA. The use of a less invasive and more user-friendly primary screening
strategy (such as self-collected swabs for HPV DNA testing) may be required to achieve the coverage necessary for effective
reduction in cervical cancer mortality.
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Introduction
Broad adoption of effective Pap smear screening programs is
credited with a substantial reduction in cervical cancer incidence
in many countries, but it has not been possible to implement this
strategy in the developing world, which bears 80% of the global
burden of cervical cancer. The reasons for this failure include a
lack of infrastructure, requirement of specialized training,
requirement of multiple visits by the woman for follow-up and
treatment, the difficulties in implementing quality controls for the
procedures, and lack of facilities to provide the needed treatment.
Therefore, over the last decade, efforts to reduce the global
cervical cancer burden through screening have focused on
development and evaluation of alternative screening assays to
the Pap smear. Two such assays have been widely promoted:
visual inspection of the cervix following acetic acid application
(VIA) and molecular tests for the presence of high risk human
papillomavirus (HR-HPV) infection [1,2]. VIA offers important
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are available immediately and in many instances, cryotherapy
treatment can be provided at the same visit. HPV DNA testing
offers the advantage of an objective assay for the presence of the
viruses which are responsible for cervical cancer.
While both of these assays have been rigorously evaluated in
controlled research settings [3,4,5,6,7,8,9,10], few studies have
reported on the effectiveness of these alternative assays for
detection of pre-neoplastic disease and cancer when implemented
in a typical health care delivery setting using limited outside
resources. In order to provide a bridge between well-controlled
research studies and programmatic implementation, we addressed
the following aims in women age 25 years and older in a
population-based study in Medchal Mandal, a peri-urban rural
community in the state of Andhra Pradesh, India: (1) evaluate the
effectiveness of using VIA, PAP, and HPV DNA testing to detect
CIN2+ and (2) evaluate the implementation of cervical cancer
screening within the local health care system. We used only readily
available local resources for training and implementation. The
results of this study provide estimates of screening coverage, rates
of follow-up visits, performance characteristics of the screening
assays, and estimates of the disease burden in the population in a
rural region in India.
Materials and Methods
Ethical Considerations
The study protocol was approved by the Institutional Review
Boards at SHARE India, MediCiti Institute for Medical Sciences
and Johns Hopkins University. Written informed consent was
obtained by signature or thumbprint.
Study Setting
REACH, or Rural Effective Affordable Comprehensive
Healthcare, was designed by SHARE India, a non-governmental
organization, to develop a replicable working model of heath care
delivery that offers preventive, primary, and secondary health care
to a rural population (http://www.sharehealth.net/). The
REACH project is centered in MediCiti Institute of Medical
Sciences (MIMS) centrally located in the rural community it
serves, 32.4 km north of Hyderabad. Combined use of ambulatory
units staffed with a doctor, nurse and health supervisor and a team
of community health volunteers (CHVs) facilitates frequent
contact with the population in their communities. The REACH
project is supported by intensive information technology (IT), with
enumeration of the population in the targeted areas specifically, in
Medchal Mandal in Ranga Reddy District, Andhra Pradesh. The
census data are acquired by household surveys, and contact
information as well as pertinent health indicators for the members
of each household are maintained by computerized database.
These data are updated annually. The combined resource of up-
to-date census information and mobile health units afford a unique
opportunity for evaluation of screening programs.
Study design
Using a census list of the Medchal Mandal community, we
approached all eligible women from 42 villages to participate in
the CATCH Study from January 2005 to July 2007. The total
population in the 42 villages was approximately 45,800, with
individual village population ranging from 46 to 4712. The villages
were located 0.5 to 25 kilometers from the MediCiti Hospital.
Individual house-to-house recruitment with personal invitation
was conducted in 35 villages; village level invitation was used in
the remaining 7 villages. Women were eligible if they were 25
years or older, had an intact uterus, were mentally competent, and
were able and willing to provide informed consent.
All consenting women were transported to MediCiti Hospital
where they received three tests for early detection of cervical
cancer and neoplasia (VIA, Pap smear, and HPV DNA) and were
then transported back to their villages. To obtain data for
correction of verification bias, 20% of the enrolling women were
randomized to receive colposcopy (immediate colposcopy arm) on
the day of the enrollment screening exam regardless of screening
test results. As soon as the results of all three tests were available, in
about 3–4 weeks after the screening visit, the women were
contacted at their homes and informed of their test results by a
health supervisor. Women who were positive by any one or more
of the screening tests (excluding women who were already
colposcoped at their first visit) were asked to return to the hospital
for a colposcopic examination. The screening and any required
treatment were provided at no cost to the participant, who was
also provided lunch and 2 kg of rice as an incentive for
participation.
Recruitment
Recruitment was conducted in two phases, systematically
covering one village at a time. In the first preparatory phase, the
elected village leader (Sarpanch) and the MediCiti CHV were
contacted by the REACH project community liaison and the
project health counselors to explain the project and obtain support
to recruit in the village. Preparatory mass education programs on
gynecologic health and cervical cancer prevention were delivered
to the community prior to systematic house-to-house recruitment
efforts. In the second phase, age-eligible women were recruited
from their house by a team of health supervisors and health
counselors. Additional education and detailed explanation of the
screening goals and procedures was provided at that time. This
‘motivation’ phase was conducted in the evenings, and women
who expressed interest and willingness to be screened were
scheduled to be picked up by hospital vehicles the following
morning for transportation to the screening clinic. Women came
to the hospital in groups of 5-30 women per day (average 10 per
day).
Screening visit
Upon arrival at the clinic, a printed consent form was read
aloud to them as a group, and each woman was privately queried
as to her understanding of the consent and given an opportunity to
ask questions. Women who agreed to participate provided a
signature or thumbprint on the printed consent form in the
presence of a witness. After consent, women responded to a brief
interviewer-administered questionnaire designed to assess demo-
graphic information as well as cervical cancer screening,
reproductive, contraceptive, and tobacco use histories.
Screening test methods
During a speculum examination, trained gynecologists collected
(in order) ecto- and endo-cervical cells for Pap smear, exfoliated
cervical cells for HPV DNA testing, and evaluated the cervix after
acetic acid application (VIA). Any abnormalities found after
examination of the vulva, vagina, and cervix (e.g., discharge,
inflammation, clinical diagnosis of STI, etc.) were recorded on a
standardized pelvic exam form. This form also allowed systematic
recording of any prescribed medication as a result of the pelvic
exam (e.g., antibiotic, antifungal). For the women randomized to
receive colposcopy at enrollment, the colposcopic exam was
performed after collection of specimens for Pap smear and HPV
DNA testing and after conducting VIA.
Cervical Cancer Screening
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After removing any obscuring mucus from the cervix with a
cotton swab, exfoliated ectocervical cells were collected and
smeared onto a glass slide using an Ayres spatula. Endocervical
cells were collected by endocervical brush and placed onto the
same slide. Cells were fixed by placing the slides in ethanol. Slides
were stained according to standard protocols, and reviewed by a
trained local cytopathologist, who recorded the cytologic diagnosis
on standardized forms according to the 2001 Bethesda System
[11]. Women with a cytologic diagnosis of ASC-US or more
severe lesion were scored as Pap smear positive. We considered the
few women with unsatisfactory Pap smear results as Pap negative
(n=86; 3.8%) rather than recalling them for a repeat Pap smear,
since logistically repeating the Pap in resource poor areas will not
be feasible.
HPV sample collection, detection, and interpretation
Following collection of the Pap smear, a Digene conical brush
sampler was placed in the cervical os, rotated 360u three times,
removed, and placed into 1 ml of Digene standard transport
medium (STM). Samples were stored at 4uC for no more than
24 hours after collection before aliquoting and long term storage
at 220uC. HPV DNA testing was performed locally using the
hybrid capture 2 (hc2) test according to the manufacturer’s
instructions. Samples with an RLU/CO value $1.0 were
considered to be positive for high risk HPV.
VIA methods and interpretation
Using standard interpretation guides [12], a positive VIA
outcome was defined as ‘‘sharp, distinct, well-defined, dense
(opaque, dull, or, oyster white) aceto-white areas with or without
raised margins, abutting the squamo-columnar junction in the
transformation zone’’ or ‘‘strikingly dense aceto-white areas in the
columnar epithelium’’ or ‘‘condyloma and leukoplakia occurring
close to the squamo-columnar junction turning intensely white’’ 1
minute after the application of a 5% acetic acid solution.
Follow-up and colposcopy
Women requiring colposcopic examination because of a positive
screening test result were contacted at their homes, and a hospital
vehicle was provided for transportation to and from the clinic. The
colposcopist was aware that referred patients had at least one
positive screening test, but was masked to the specific VIA, Pap,
and HPV DNA results. Even though the VIA test results were
available immediately at the time of screening, referral to
colposcopy was made only after all three test results were
available. Biopsies were taken from any suspicious lesion. All
biopsies were read locally, and were subsequently reviewed by an
expert pathologist at Johns Hopkins Medical Institutions (JHMI).
Women with histologically confirmed cervical intraepithelial
neoplasia (CIN) grade 2 or 3 by either local or JHMI review
were referred for treatment by LEEP/cold knife conization or
hysterectomy. Women found to have operable invasive cancer
were treated at MIMS. Women requiring radiotherapy were
referred to the government cancer hospital. A release form was
signed by any woman with CIN2+ who refused treatment.
Statistical Methods
Differences in test positivity by age were assessed using
Pearson’s chi-square tests. Test agreement was measured using
kappa statistics with 95% confidence intervals. The agreement
between the JHMI and MIMS diagnosis of ,CIN2 vs. CIN2+ was
good (94.9% total agreement, 60.9% percent positive agreement).
For this analysis, cases were defined based on the JHMI pathology
diagnosis. Diagnostic accuracy statistics (sensitivity, specificity, and
positive/negative predictive values (PPV/NPV) were calculated
for each of Pap, VIA, and HPV testing for each of CIN2+ and
CIN3+ outcomes. Crude estimates of diagnostic accuracy were
biased due to non-random exclusion of women who did not have
the opportunity for full diagnostic verification (i.e., women who
screened negative and were not randomized, or, referred women
who refused colposcopy and/or biopsy) [13]. To properly account
for this verification bias, we used inverse-probability weighting to
weight up women with observed histology to represent the full
cohort of 2331 women. We extended methods previously
developed to account for verification bias under stratified two-
phase sampling to three-phase sampling with sampling strata
defined by the eight combinations of Pap, VIA, and HPV test
results (e.g. +++, ++2, etc.). First, the 670 women who accepted a
biopsy and had histology results were weighted up (within
sampling strata) to represent all 781 women who appeared for
colposcopy. Second, the 781 women who appeared for colposcopy
were weighted up to represent the full cohort of 2331 women who
consented. This correction for verification bias assumes that
women who refused a colposcopic exam or who refused an
indicated biopsy have the same disease rates as women who
accepted the exam and biopsy, respectively, within each sampling
stratum.
Results
Participation in screening and diagnostic follow-up
procedures
The degree of participation in the study and compliance with
screening and diagnostic follow-up is summarized in Figure 1,
stratified by immediate colposcopy arm and by overall screening
test results. A total of 5603 women were determined to be eligible
for screening and were invited to participate by at least one
person-to-person contact. Of these, 2331 (41.6%) enrolled and
completed the screening protocol; the remainder refused partic-
ipation. As targeted in the study protocol, approximately 20% of
consenting women were randomized to receive an immediate
colposcopic examination following their screening tests at the
enrollment visit (455/2331, immediate colposcopy arm). In
addition, 582 women not randomized to immediate colposcopy
but testing positive by any one or more of the three screening tests
were referred back for a colposcopic examination at a second visit.
Disease ascertainment was incomplete in both arms. In the
randomized arm, a total of 114 women (25%) had a colposcopic
abnormality where a biopsy was indicated; of these women, 61
(53.5%) refused biopsy. In the referred arm, 582 of the 1876
women (31%) were screen-positive and were referred for
colposcopy; of these, 256 women (44.0%) did not return for the
colposcopic follow-up. Among those who did come for the follow-
up visit, 165 (50.6%) had a colposcopic abnormality indicating
biopsy, with 45 (27.3%) refusing biopsy (significantly lower than
biopsy refusal among women with immediate colposcopy (53.4%,
p,0.001).
Baseline demographics
The baseline demographics of the enrolled population are
presented in Table 1. Consistent with the age-specific participation
rates, the enrolled cohort was skewed toward younger ages, with
48% of women between 25–34 years (mean age 37.4 years, SD
11.1). Most participants identified themselves as Hindu (86.8%)
and had no formal education (69.4%). Most women were either
unemployed/housewives (32.6%) or worked in agriculture
Cervical Cancer Screening
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or in the past); therefore we considered the age women first lived
with husband (shobhanam) as the best surrogate marker of sexual
debut. These data were normally distributed with a mean age at
shobhanam of 15.6 years (SD 2.8). A few women (13.1%) reported
use of tobacco products, and the majority of this was pan (betel
leaf) use (93.4%). A more substantial fraction reported passive
tobacco smoke exposure (37.9%). Most women were parous
(96.8%), with a median of 3 live births. Most women (95.5%)
reported no previous pap screening.
Test positivity by age
The population prevalence of positive results was similar by
screening method (12.7%, 14.6%, and 10.3% for VIA, Pap, and
HPV, respectively). HPV prevalence did not vary significantly by
age (p=0.44), while Pap prevalence increased significantly with
increasing age (p,0.001)) (Table 2). VIA prevalence did not vary
by age among women 25–60 years (p=0.59), but was significantly
higher among women over age 60. We recognize that once- or
twice-in-a-lifetime screening is usually recommended for women
in a more narrow age range (e.g., 25–50 years). When we
restricted our analysis to women in that age range, the prevalence
of positive test results was more similar across testing methods
(12.1%, 11.1%, and 10.0% for VIA, Pap, and HPV, respectively).
Concordance of test positive
A total of 733 (31.4%) women were positive by one or more
tests, while only 16 (0.7%) were positive for all three tests. The
agreement was better between Pap and HPV DNA tests compared
to either of these assays and VIA, but agreement beyond that
expected by chance was poor in all comparisons (kappa range
0.04–0.11). In order to better understand the disagreement
between test results, we tested approximately 19% of VIA- and
Pap-positive, but hc2 negative samples using consensus primer
PCR [14,15]. Only 2 of 52 (4%) VIA positive/hc2 negative
samples, but 19 0f 95 (20%) of Pap positive/hc2 negative samples
tested positive for HPV by PCR, mostly for low-risk HPV types.
Crude test performance for detection of CIN2/3/cancer
We detected a total of 19 CIN2+ cases; 8 CIN2, 7 CIN3, and 4
invasive cancers. We first calculated the crude assay performance
only among those women who had a colposcopic examination and
did not refuse biopsy when indicated (N=675); normal colposcopy
results were considered to be negative for CIN2+. Our results
Figure 1. Participation in screening and follow-up (colposcopy and biopsy where recommended) by randomization arm and
screening result. Screen positive indicates positive result on VIA, Pap, and/or HPV DNA testing. Colposcopy normal indicates no area of abnormality
identified, no biopsy recommended. Colposcopy abnormal-biopsy taken indicates that a biopsy was successfully obtained from all visually identified
areas of abnormality. Colposcopically abnormal-biopsy refused indicates that a lesion was visualized and biopsy recommended, but the patient
refused.
doi:10.1371/journal.pone.0013711.g001
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with HPV DNA testing having the best sensitivity and specificity
when defining cases as CIN2+ or CIN3+ (84.2% and 81.3% for
CIN2+; 100% and 80.72% for CIN3+). The next best test was Pap
with lower sensitivity (63.2% and 81.8% for CIN2+ and CIN3+,
respectively) and specificity (76.2% and 76.1% for CIN2+ and
CIN3+, respectively) compared to the HPV DNA test. VIA
demonstrated both poor sensitivity and specificity in this analysis
(26.3% and 76.4% for CIN2+ and 36.4% and 76.5% for CIN3+).
Accordingly, the HPV DNA test showed both high positive
predictive value (11.5%) and negative predictive value (99.4%) for
CIN2+.
Adjusted test performance. Using inverse-probability weighting, we
applied the CIN2+ and CIN3+ rates from women with
colposcopy-biopsy results to the full cohort, as described in
Methods. One case of CIN2 was detected among the 304 screen-
negative women in the immediate colposcopy arm, for a disease
prevalence of 0.33%. The verification bias adjusted estimates of
test performance are shown in Table 3B. The relative perfor-
mance of HPV.Pap.VIA was similar to that observed in the
crude estimate, though as expected the sensitivity estimates for
each test decreased while specificity estimates increased, especially
when cases included CIN2 lesions. HPV testing remained more
Table 1. Demographics of study population.
N% N %
Age (years) Use of any tobacco (self)
25–29 659 28.3% No 2026 86.9%
30–34 460 19.7% Yes 305 13.1%
35–39 351 15.1% Live with a smoker
40–44 256 11.0% No 1448 62.1%
45–49 199 8.5% Yes 883 37.9%
50–54 131 5.6% Parity
55–59 106 4.5% 0 75 3.2%
60+ 133 5.7% 1 128 5.5%
missing 36 1.5% 2 569 24.4%
Religion 3–4 1094 46.9%
Hindu 2023 86.8% 5+ 465 19.9%
Muslim 99 4.2% Previous Pap history
Christian 208 8.9% None 2223 95.4%
Other 1 0.0% Yes 27 1.2%
Education (highest level completed) don’t know 79 3.4%
none 1606 68.9% missing 2 0.1%
1–8 435 18.7% Age first lived with husband (years)
9 or more 272 11.7% ,10 12 0.5%
missing 18 0.8% 10–13 589 25.3%
Occupation (self) 14–16 897 38.5%
housewife/unemployed 702 30.1% 17–19 570 24.5%
laborer 229 9.8% 20–36 213 9.1%
agriculture 846 36.3% missing 50 2.1%
self-employed 163 7.0%
government employee 18 0.8%
private company/other 193 8.3%
missing 180 7.7%
doi:10.1371/journal.pone.0013711.t001
Table 2. Age-specific positive screening test prevalence.
TOTAL VIA positive Pap positive HPV positive
AGE
(years) N% % %
25–29 659 10.2% 7.9% 10.5%
30–34 460 13.7% 9.1% 10.9%
35–39 351 12.8% 10.3% 8.0%
40–44 256 11.7% 11.7% 9.0%
45–49 199 14.1% 25.1% 11.6%
50–54 131 13.7% 32.1% 15.3%
55–59 106 12.3% 34.9% 8.5%
60+ 133 24.8% 36.8% 10.5%
TOTAL 2295 12.9% 14.7% 10.3%
These estimates exclude 36 women with missing age.
doi:10.1371/journal.pone.0013711.t002
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to VIA (sens=16.7%; spec=87.4%) and Pap (sens=46.5%;
spec=86.0%). Sensitivity was increased substantially for all three
tests when CIN2 was removed from the case definition (100.0%,
78.2%, and 31.6% for HPV, Pap, and VIA, respectively).
Estimates of disease burden in the population
Using the data generated from applying the probability weights
to the entire eligible cohort (N=5603), we estimated a CIN2+
prevalence of 3.8% and a CIN3+ prevalence of 1.6%. This model
predicts that 57.1 ‘true positive’ cases of CIN2+ (23 cases of
CIN3+) would have been detected with complete follow-up (100%
colposcopy and 100% biopsy where indicated), and an additional
137.3 ‘true positive’ cases of CIN2+ (55.4 cases of CIN3+) would
have been detected if the entire eligible population had been
screened. Figure 2 summarizes the estimated burden of CIN2+ in
the population in relation to the cases detected by the hc2 assay.
Treatment
Of the 19 women who had CIN2+, we provided LEEP for 2,
hysterectomy for 9, and referral to the cancer hospital for radiation
therapy for 4 women who had invasive cancer. Four women
refused treatment despite several direct visits by the study
gynecologist for direct counseling.
Discussion
When evaluated as a complete program, the greatest threat to
realizing a reduction in cervical cancer mortality was non-
participation in the program and among those who participated,
non-compliance with some aspects of the screening requirements,
rather than the use of a less accurate screening test. Using standard
population-weighted methods to correct for incomplete verifica-
tion of disease status, we estimated that 86.2% of the potential
underlying cases of CIN2+ may have been missed due to program
failures; 27.8% as a result of incomplete compliance with follow-up
procedures (e.g., colposcopy and biopsy), and 58.4% as a result of
non-participation in the screening program. We therefore
conclude that despite our use of available resources, infrastructure,
and guidelines for cervical cancer screening implementation in
resource limited areas developed by the Alliance for Cervical
Cancer Prevention (ACCP) [12], community participation and
non-compliance remain the major obstacles to successful reduction
in cervical cancer mortality in this Indian population and that a
more user-friendly screening strategy which reduces the need for a
clinic visit may vastly increase coverage.
Participationevenintheprimaryscreeningphaseinourstudywas
low (38%). Evaluations of the screening test alternatives reporting
coverage typically show participation rates at or above the 70%
threshold thought to be required for effective reductions in cervical
cancer mortality [9,10,16,17,18,19]. One exception is the study by
Nene, et al which reported participation of 56.4% [20]. We cannot
readily explain the lower participation in our study compared to
other reports of cervical cancer screening in India. One possibility is
publication bias, where only studies with participation nearing the
70% effectiveness threshold report participation. In our review
of 21 studies comparing alternative screening methods, the
majority (14/21, 67%) did not report participation rates at all
[5,6,8,9,10,16,17,18,20,21,22,23,24,25,26,27,28,29,30,31,32].
A detailed assessment of reasons for refusal will be described
separately; in general, older women and women with lower
household income were least likely to participate. We conducted
focus groups to understand the attitudes of the women in our
population toward participation in the screening program.
Reluctance to participate was related to the perception that there
was no need to go the clinic when they had no symptoms. When
probed further, they cited fear/anxiety as a significant factor for
reluctance to participate; fear of a cancer diagnosis, of pelvic
examination and of community gossip and perception (unpub-
lished data). We revised our educational material in response to
the concerns elicited through the focus group. While we did not
see any change in participation among women with the lowest
reported income, participation improved in the middle- and high-
income groups as a result of this intervention.
Table 3. Test performance characteristics.
A. Among women with full colposcopy and histologic evaluation (N=675)
Sensitivity (95% CI) Specificity (95% CI) PPV (95% CI) NPV (95% CI)
CIN2+ Pap 63.20% (38.4%–83.7%) 76.20% (72.8%–79.4%) 7.14% (3.75%–12.1%) 98.60% (97.2%–99.4%)
VIA 26.30% (9.2%–51.2%) 76.40% (72.9%–79.6%) 3.13% (1.02%–7.14%) 97.30% (95.5%–98.5%)
HPV 84.20% (60.4%–96.6%) 81.30% (78%–84.2%) 11.50% (6.72%–18%) 99.40% (98.4%–99.9%)
CIN3+ Pap 81.82% (48.22–98.72%) 76.05% (72.62–79.25%) 5.36% (2.48–9.93%) 99.61% (98.58–99.95%)
VIA 36.36% (10.93%–69.21%) 76.51% (73.09%–79.68%) 2.50% (0.69%–6.28%) 98.64% (97.22%–99.45%)
HPV 100.00% (71.51%–100.00%) 80.72% (77.51%–83.66%) 7.91% (4.02%–13.72%) 100.00% (99.31%–100.00%)
B. Among total screened population, verification bias adjusted estimates (N=2331)
Sensitivity (95% CI) Specificity (95% CI) PPV (95% CI) NPV (95% CI)
CIN2+ Pap 46.50% (28.67%–65.30%) 86.04% (85.59%–86.47%) 7.72% (5.04%–11.66%) 98.46% (97.08%–99.20%)
VIA 16.65% (8.53%–29.98%) 87.36% (87.10%–87.61%) 3.20% (1.74%–5.83%) 97.66% (96.30%–98.53%)
HPV 61.21% (38.45%–79.95%) 90.98% (90.46%–91.48%) 14.56% (10.07%–20.60%) 98.94% (97.52%–99.55%)
CIN3+ Pap 78.24% (53.48%–91.84%) 85.88% (85.55%–86.20%) 5.24% (3.22%–8.42%) 99.75% (99.29%–99.91%)
VIA 31.56% (16.32%–52.16%) 87.45% (87.26%–87.63%) 2.45% (1.28%–4.65%) 99.23% (98.64%–99.56%)
HPV 100.00% (na) 90.60% (90.20%–90.99%) 9.60% (6.14%–14.72%) 100.00% (na)
A. Crude estimates among women with full colposcopic and histologic evaluation (N=675). B. Verification-biased adjusted estimates among total screened population (N=2331).
CIN: cervical intraepithelial neoplasia, CI: confidence interval, PPV: positive predictive value, NPV: negative predictive value
doi:10.1371/journal.pone.0013711.t003
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reported by Basu [33] in cervical cancer screening in Kolkata.
Specifically, in the Kolkata study, among women declining
screening by their own choice, 46.1% cited ‘I do not need any
check up since I have no complaint’ as the reason for not attending
the screening visit. Other commonly cited reasons for non-
participation in their standardized survey included fear of the tests
(36.2%), adverse effects of the screening procedure reported by
neighbor/relative (27.6%), feeling shy to have the exam (26.7%),
and a desire to let fate/God guide destiny (18.5%) [33]. It was
interesting to note that some women who declined to participate in
the Calcutta study stated that they would ‘get the test done in
private institutions with better facilities’. It is possible that in
communities with access to multiple health care venues, as is the
case in our study population in Medchal Mandal (including private
hospitals, NGO-affiliated hospitals, and government hospitals),
competition and perceived quality of care could be influential in
choice of cervical cancer screening programs.
Among women screened, substantial differences in test perfor-
mance for Pap smear, VIA, and HPV DNA tests were observed.
As expected, adjustment for verification bias decreased sensitivity
and increased specificity for all tests. The sensitivity estimates for
HPV testing, particularly for detection of CIN3+, are generally
consistent with prior studies [4,7,8,9,34,35], while the sensitivity
for VIA was remarkably lower than previous reports. The lower
sensitivity of VIA was explored in detail in a separate manuscript
[36] which showed a strong inter-rater variability as well as a non-
specific reactivity in the presence of inflammation. A second
possible explanation for our lower sensitivity estimates of VIA
could be related to study design. Specifically, because we did not
use a screen-and-treat approach in the VIA arm, referral of
women testing positive by VIA was delayed by the same interval as
those testing positive by hc2 and Pap cytology. This minimized
any bias that resulted from lesions that regressed between
screening and follow-up [37] and the correlative bias between
VIA and colposcopy which rely on similar visual clues [13,38],
which could have led to an overestimation of sensitivity in other
studies. Alternatively, VIA is not recommended for women over
age 50 years. We did not place an upper age restriction for
participation in this study because we felt that in our population of
women who had never been screened, everyone could benefit
from at least one of the 3 screening tests (HPV testing performance
is not compromised in older women). Since 6/19 (31.6%) of our
cases would have been lost with age restriction, we presented the
unrestricted performance data. However, inclusion of women over
age 50 years could have led to an underestimated sensitivity for
VIA. The sensitivity of Pap testing at an .= ASC-US threshold
was moderate. We note that the specificity of Pap smears was
lower than most studies, which is likely attributable to the increase
in ASC-US diagnosis in older women (Table 2), possibly the result
of misinterpretation of cellular changes secondary to hormonal
declines during menopause. We evaluated the use of alternative
thresholds for Pap positivity (eg., LSIL, HSIL) to improve the test
specificity, but found these to result in a significant reduction in
test sensitivity (data not shown). The fact that HPV PCR was
positive (predominately with low risk types) in a higher proportion
of Pap positive/hc2 negative samples, compared with VIA
positive/hc2 negative samples, suggests that while most of the
false positive VIA results were unrelated to HPV-associated
changes, some positive Pap smears may reflect cellular changes
due to infection with low-risk HPVs.
When we removed CIN2 from the case definition, the
performance estimates increased for all tests. Verification bias-
adjusted sensitivity for CIN3+ was 100.0% for HPV, 78.2% for
Pap, and 31.6% for VIA. The uncertainty of CIN2 diagnoses in
detecting women with true precancerous lesions is well-described
[39]. In our study, two of three hc2-negative CIN2 cases were also
negative for 37 HPV genotypes detected by PCR (Roche Linear
Array) in swabs collected at both the screening and the diagnostic
visits. This suggests that the morphologic changes were unrelated
Figure 2. Estimated proportion of cases of CIN2+ observed and estimated via population weighting for verification bias
adjustment. Screen detected indicates proportion of cases of CIN2+ detected by hc2, and screen undetected indicates the proportion of CIN2+ cases
detected through the screening program, but missed by hc2. Refused biopsy indicates the proportion of CIN2+ cases estimated among those who
refused biopsy, refused colposcopy indicates the proportion of CIN2+ cases estimated among those who screened positive, but refused colposcopic
exam, and refused involvement indicates the proportion of CIN2+ cases estimated among those who refused participation in the program (i.e., not
screened).
doi:10.1371/journal.pone.0013711.g002
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magnified in verification bias-adjusted estimates, raising questions
as to the validity of test performance metrics when including CIN2
in the case definition. A case definition which combines
morphologic and molecular criteria (e.g., p16 staining, multiple
HPV tests) may be useful for future evaluations of screening test
performance to avoid misclassification bias.
Our study has limitations. The low number of cases detected in
our study likely reflects an under-ascertainment of disease. Our
case definition was based on histologically confirmed CIN2+ from
colposcopically-directed biopsy. This is a flawed reference
standard [40] and likely to miss a substantial proportion of
underlying CIN2+ lesions [34,38]. Specifically, we detected 19
cases of CIN2+ in our study, representing an overall prevalence
among the population of women with full colposcopic and
histologic evaluation of 2.8% (CIN2/3=2.2%; cancer=0.6%).
The observed CIN2+ prevalence among all fully screened women
was 0.8% (CIN2/3=0.6%; cancer=0.2%). We note, however,
that these estimates are largely consistent with those in a large
study of over 140,000 women in Maharashtra State which
reported CIN2-3 prevalence ranging from 0.7%–1.0% and cancer
prevalence ranging from 0.2%–0.3% [19]. In comparison to the
observed prevalence, our estimates of prevalence following inverse
probability weighting to the entire population were somewhat
higher (3.8% and 1.6% for CIN2+ and CIN3+, respectively).
These prevalence estimates may be inflated, since we did not
further stratify the subgroups by age and other determinants of
CIN2+. The small number of observed cases precluded additional
levels of stratification for the inverse probability weighting.
Compliance with follow-up colposcopy and biopsy were also
low in our study. Losses to follow-up are well-described barriers to
cervical cancer screening in resource-limited populations, and
therefore the colposcopic refusal results are not entirely unexpect-
ed. Our follow-up may have been lower than that reported in
other studies [9,19] because we were unable to provide
colposcopic exams at peripheral field sites. However, follow-up
rates were similar by village and did not decrease with increasing
distance from the hospital. Women were approached up to 3 times
to encourage participation in colposcopy, sometimes by the study
gynecologist, before we considered the participant lost to follow-
up. When we probed for reasons for non-compliance with follow-
up in focus groups, the majority reported that they would wait
until they developed symptoms. A few suggested that they were
seeking treatment outside of the study. We required verbal consent
prior to taking biopsies, which may have reduced compliance with
this procedure. We did not systematically document reasons for
refusing biopsy. The higher biopsy refusal in the group who were
randomized to immediate colposcopy could represent a mix of
women who would and would not have returned for a follow-up
colposcopy if referred.
Our study also has several strengths. Use of the census data
from an entire Mandal allowed us to calculate population-based
estimates of test performance as well as compliance with screening
and diagnosis. In addition, each woman received all three
screening tests, allowing for direct comparison of test performance,
which was not possible in large community randomized trials. Use
of PCR testing to confirm discrepant results also enhanced our
understanding of the lack of correlation in the screening test results
by providing a second objective measure.
In conclusion, our results suggest that currently proposed
algorithms for cervical cancer screening in resource limited regions
are still plagued by infrastructural and compliance barriers. We
have previously reported that participation rates may increase
substantially if the primary screening is offered in the village by
self-collection of samples for HPV testing [41]. Programmatic
changes such as village-based self-sampling may therefore offer
alternatives strategies for increased participation in cervical cancer
screening in resource poor regions. However, successful reduction
of cervical cancer burden will require development of acceptable
strategies for follow-up of screen positive women. For example, in
our study[41] only 34.8% of women who were found to be HPV
positive as a result of village-based self-sampling returned for
colposcopic examination. Finally, establishment of regional
programs of cervical cancer screening of older women linked with
programs for immunization of younger women may be expected
to reduce the burden of cervical cancer in resource-limited regions
of the world. The tools to substantially reduce the global burden of
cervical cancer are available or will soon become available.
Realistic evaluation of sustainable program implementation will be
critical to ensure that the tools are used to maximum benefit with
the least cost.
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